Dear JDRF Advocates,

With the deadline rapidly approaching, we still need more comments to be submitted to NIH in support of their guidelines for embryonic stem cell research. Please help!

 

Please review the 3 steps below to review and submit the prepared comments. Additional issue background can be found at the bottom of this email.

 

Stem Cell Research Guidelines Comment Form

 

1. Click here to be directed to the comment form, provide your name and select ‘Self’ for Affiliation. (JDRF, as an organization, will provide comments directly to the NIH.)

 

2. Copy and paste the text (below) into the Comments section, provide the security check ID on the form and click ‘Submit Comments’.

3. Once you have completed steps 1 and 2, please click hereto let us know you have completed the action so we can track the number of JDRF advocates participating.

Be sure to pass this message on to your family and friends, we need to generate as many comments as possible to support our efforts for a cure!

 

Comment Text (please copy and paste into Comments section)

 

For many Americans with a personal connection to type 1 diabetes, the Administration’s expansion of the federal policy on embryonic stem cell research has renewed our hope for a cure. I am writing today to support the National Institutes of Health’s (NIH) draft guidelines and suggest a change to ensure promising, ethically conducted research currently underway will be eligible for federal funding in the future.

 

The Administration’s Executive Order on stem cell research restored scientific decision-making to its rightful place at the NIH. In these guidelines, the NIH has demonstrated its capacity to formulate a research framework that will unleash the potential of embryonic stem cell research while maintaining the highest safety and ethical standards.  I would encourage the NIH, however, to grandfather into this policy stem cell lines that have received federal funding, as well as existing lines that were derived in an ethically-responsible manner according to the best practices at the time. Research on these stem cell lines should be eligible for federal funding so that scientists can maximize the scientific advancements already achieved through research on these lines.

 

Research should be vigorously pursued on all promising stem cell sources that could potentially lead to a cure for type 1 diabetes. While embryonic stem cell research is still in its early stages, this research has already yielded impressive results in our continuing effort to find a cure for type 1 diabetes. Recent research suggests that embryonic stem cells can be differentiated to produce the insulin-producing beta cells that could reverse the course of type 1 diabetes.

 

We do not yet know which stem cell sources may ultimately lead to a cure or be the most clinically useful or practical for patients with type 1 diabetes. It is clear, however, that the more knowledge we gain about embryonic stem cells, the better we can assess the full therapeutic potential of all stem cell sources. These draft guidelines allowing federal funding for embryonic stem cell research using excess embryos from fertility clinics will ensure that this research matures and its potential is more fully realized. I commend the NIH for allowing this important research to expand in a scientifically and ethically appropriate manner.